Bacteremia Clinical Trial
Official title:
Single-center, Before-and-after Study Evaluating the Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU Patient
Bacteremia is a frequent infection in intensive care units. It is associated with a high mortality rate and the rapid implementation of appropriate antibiotic therapy is strongly correlated to patient clinical outcomes. Innovative technologies have emerged to shorten the turnaround time of blood culture samples by obtaining susceptibility testing of the incriminated pathogen at an early stage, and therefore to rapidly adjust the antibiotic therapy of patients with Gram-negative Bacilli bacteremia. The study investigators hypothesize that the implementation of the innovative BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® solutions for the analysis of blood culture samples will increase the proportion of patients with Gram-negative Bacilli bacteremia who receive appropriate and optimized antibiotic therapy 24 hours after blood culture collection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
| Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
| Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
| Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
| Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
| Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
| Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
| Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
| Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
| Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
| Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
| Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
| Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
| Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
| Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
| Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
| Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |